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Abstract: Recently the tryptophan pathway has been considered an important determinant of
HIV-1 infected patients’ quality of life, due to the toxic effects of its metabolites on the central
nervous system (CNS). Since the dysbiosis described in HIV-1 patients might be responsible for the
microbial translocation, the chronic immune activation, and the altered utilization of tryptophan
observed in these individuals, we speculated a correlation between high levels of immune activation
markers in the cerebrospinal fluid (CSF) of HIV-1 infected patients and the over-expression of
indolamine-2,3-dioxygenase (IDO) at the gut mucosal surface. In order to evaluate this issue,
we measured the levels of neopterin in CSF, and the expression of IDO mRNA in gut-associated
lymphoid tissue (GALT), in HIV-1-infected patients on effective combined antiretroviral therapy
(cART), at baseline and after six months of probiotic dietary management. We found a significant
reduction of neopterin and IDO mRNA levels after the supplementation with probiotic. Since the
results for the use of adjunctive therapies to reduce the levels of immune activation markers in CSF
have been disappointing so far, our pilot study showing the efficacy of this specific probiotic product
should be followed by a larger confirmatory trial.
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1. Introduction
A key role of tryptophan metabolism in causing the chronic immune activation status in patients
with HIV-1 infection has been proposed [1,2]. Altogether, these aspects are relevant in the context of the
contribution of the microbiota composition in modulating the gut–brain axis (GBA) [3]. The discovery
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that differential gut microbial composition is associated with alterations in behavior and neurocognitive
functions has significantly contributed to establish the “microbiota–gut–brain-axis” as an extension
of the well-accepted GBA concept [4]. The latter is generally used to describe the existence of a
bidirectional communication network between the CNS and intestinal organs, including the enteric
nervous system (ENS) [3]. Here, we speculate that the presence of a dysfunction in tryptophan
metabolism during HIV-1 infection may contribute to a disruption of the integrity of the intestinal
mucosal barrier, worsen microbial translocation, and, indirectly, immune activation status. In particular,
the gut associated lymphoid tissue (GALT) is considered to be one of the preferential sites of HIV-1
replication, and members of the class Clostridia have been found to induce mucosal expression of
indolamine-2,3-dioxygenase (IDO) [5]. Directly related to this, HIV-1 infected patients are likely to
harbor enteropathogenic bacteria that can catabolize tryptophan into immunomodulatory kynourenine
derivatives, known to correlate with disease progression and mucosal immune disruption [6]. Indeed,
it has been recently reported that HIV-1 infection leads to a significant and distinct impact on the
metabolism of the gut ecosystem compared with other diseases [7]. In the course of HIV-1 infection, the
chronic immune activation—partially due to a dysfunction of the GALT—with consequent microbial
translocation has been linked with an increased production of interferon (IFN) gamma and IDO
activity [8,9]. IDO is an enzyme involved in tryptophan metabolism, and its expression is increased
by many cytokines. This enzyme can induce an increase in kinurenine and other metabolites, such as
quinolinic acid. Those molecules have been reported to be associated with the neuronal toxicity and
neurocognitive disorders in HIV-1 infected patients [9–13]. Moreover, kynurenine can act as negative
regulators of T cell proliferation [14], while quinolinic acid is related to the onset of neurocognitive
disorders, such as the AIDS dementia complex [2]. Notably, IDO has been also associated with
a reduction in Th17 cell frequency, which plays a pivotal role in the maintenance of gut mucosal
integrity during HIV-1 infection [15,16]. Given the strong relationship between the damage of the
intestinal epithelium and the presence of altered gut microbiota composition in HIV-1 population,
and the hypothetical link with the mucosal expression of IDO, the administration of oral probiotics in
combination with combined antiretroviral therapy (cART) could limit the outgrowth of pathobionts that
exacerbate mucosal immune disequilibrium in IDO expression. Neopterin—produced by macrophages
upon IFN gamma stimulation—is a recognized marker of monocyte activation, and an association
between its expression and the development of HIV-associated neurocognitive disorders (HAND)
has been proposed [17–20]. The expression of neopterin has been found to be higher both in naïve
HIV-1-positive patients compared to those on cART and in HIV-1 infected patients on effective
cART than in healthy people [20,21]. In light of the above considerations, we performed the first
longitudinal pilot study evaluating the effects of a high concentration multistrain probiotic product
on neopterin levels in cerebrospinal fluid (CSF) and on the expression of IDO mRNA measured
in lymphocytes of lamina propria (LPLs) of the gut in cART-treated HIV-1-positive patients with
long-term virologic suppression.
2. Results
2.1. Demographic and Clinical Characteristics of HIV-1-Positive Patients
All study participants were HIV-1-positive Caucasian men with a median age of 42 years
(IQR 22–53 years). They initiated therapy during chronic HIV-1 infection and had been on cART
for a median of six years (IQR, 1.75 to 16.25 years). The median of CD4+ T cell count pre-therapy
was 255 cells/mm3 (IQR, 42.75–406.75 cells/mm3), HIV-1 RNA copies median value was 5.0 Log/mL
(IQR, 4.81–5.61 Log/mL). All subjects had been virologically suppressed (<37 HIV-1 RNA copies/mL)
for at least one year, and their median CD4+ T cell count was 674 (IQR, 564–824 cells/mm3) and 683
(IQR, 610–818 cells/mm3) cells/mm3, respectively, before and after probiotic supplementation of cART.
HIV-1 RNA and a search for neurotropic viruses were negative in all CSF samples.
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To better understand the improvement in neurocognitive functions in HIV-1-positive patients
after probiotic supplementation, we evaluated changes in IDO mRNA and neopterin levels, before
(T0), and after six months (T6) of supplementation with probiotics.
2.2. IDO mRNA Expression
We evaluated the expression level of IDO mRNA (which is involved in tryptophan metabolism) in
GALT, measuring its amount in LPL. We found that patients with HIV-1 infection had highly variable
levels of IDO mRNA before and after probiotic supplementation (coefficient of variability >100%).
Following probiotic supplementation, a significantly reduction in the IDO mRNA expression was
recorded (p = 0.04, Figure 1).
Int. J. Mol. Sci. 2016, 17, 1639 3 of 9 
 
o better understa  t e i ro e t i  ne roc iti  f ti  i  I -1- siti  ati t  
 i i  l      I    t i  l l , f  
( ),  fter six o t s ( 6) of supple entation ith probiotics. 
2.2. I   Expression 
e evaluated the expression level of IDO mRNA (which is involved in tryptophan metabolism) 
in GALT, measuring its amount in LPL. We found that patients with HIV-1 infection had highly 
variable levels of IDO mRNA before and after probiotic supplementation (coefficient of variability 
>100%). Following probiotic supplementation, a significantly reduction in the IDO mRNA expression 
was recorded (p = 0.04, Figure 1).  
 
Figure 1. Modulation of indolamine-2,3-dioxygenase (IDO) mRNA in gut-associated lymphoid tissue 
(GALT). IDO mRNA expression level before (T0) and after six months (T6) of probiotic 
supplementation in GALT of combined antiretroviral therapy (cART)-treated HIV-1-positive patients 
with suppressed HIV-1 viremia (n = 10). * p = 0.04. 
2.3. Neopterin Levels 
In order to evaluate the rate of inflammation in the central nervous system (CNS), we measured 
neopterin levels in the CSF of HIV-1-positive patients, before (T0) and after (T6) probiotic 
supplementation. We found higher levels of neopterin at T0 compared to those recorded at T6. In 
particular, a significant decrease of neopterin levels after 6 months of probiotic supplementation was 
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before (T0) and after six months (T6) of probiotic supplementation in CSF of cART-treated HIV-1-
positive patients with suppressed HIV-1 viremia (n = 10). * p < 0.004. 
Moreover, we investigated the relationship between IDO mRNA expression in the GALT and 
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Figure 1. Modulation of indolamine-2,3-dioxygenase (IDO) mRNA in gut-associated lymphoid tissue
(GALT). IDO mRNA expression level before (T0) and after six months (T6) of probiotic supplementation
in GALT of combined antiretroviral therapy (cART)-treated HIV-1-positive patients with suppressed
HIV-1 viremia (n = 10). * p = 0.04.
2.3. Neopterin Levels
In order to evaluate the rate of inflammation in the central nervous system (CNS), we measured
neopterin levels in the CSF of HIV-1-positive patients, before (T0) and after (T6) probiotic
supplementation. We found higher levels of neopterin at T0 compared to those recorded at T6.
In particular, a significant decrease of neopterin levels after 6 months of probiotic supplementation
was observed (p = 0.004, Figure 2).
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Figu 2. Modulation of neopterin levels in cerebrospinal fluid (CSF). Neopterin expression level before
(T0) and af er six months (T6) of probiotic supplementation in CSF of cART-treated HIV-1-positive
patients with suppressed HIV-1 viremia (n = 10). * p < 0.004.
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Moreover, we investigated the relationship between IDO mRNA expression in the GALT and the
level of neopterin in the CSF. We found that at T0 there is a positive correlation between IDO mRNA
expression and neopterin level, while at T6, the correlation is no longer observed (Table 1).
Table 1. Correlation between cerebrospinal fluid (CSF) neopterin levels and gut-associated lymphoid
tissue (GALT)-associated IDO mRNA expression before (T0) and after six months (T6) of probiotic
supplementation in cART-treated HIV-1-positive patients with suppressed HIV-1 viremia (n = 10).
IDO mRNA T0 IDO mRNA T6
Neopterin T0 p = 0.004; r = 0.94 NA
Neopterin T6 NA p = 0.54; r = −0.31
Spearman’s rho coefficient was used to assess the correlations between neopterin and IDO levels; significant
correlations are highlighted in bold. NA = not applicable.
3. Discussion
In this study, we focused on the relationship between the rate of CSF inflammation measured
in terms of neopterin levels and the GALT-associated expression of IDO mRNA in HIV-1-positive
patients with suppressed HIV-1 viremia under treatment with cART, before and after supplementation
with a high-dose multi-strain probiotic. The high levels of both neopterin and IDO mRNA observed at
the enrollment cannot be explained by the HIV-1 RNA levels, because all patients had undetectable
HIV-1 RNA levels, both in peripheral blood and in CSF.
It is known that the introduction of cART reduces the effects of HIV-1 on the neurological
impairment, but does not normalize them. To date, the main monocyte activation marker known
regarding CNS inflammation in HIV-1 infection is CSF neopterin [22]. In particular, neopterin is a
sensitive marker of immune activation, and it is produced by monocyte-derived cells [23]. Neopterin
detected in the CSF is originated in the CNS [24], and during HIV-1 infection is expressed at high
levels, especially in patients with HAND [25]. Despite cART, neopterin persists at higher levels
in HIV-1-positive patients compared to healthy controls, although an early decrease of its amount
in CSF is observed after initiation of therapy [23]. These data suggest an ongoing HIV-1-related
pathological process within the CNS, where a continuous neuroinflammation and axonal degradation
occurs, despite cART [24]. Moreover, enhanced cell trafficking (monocyte-derived cells) from the
periphery can enhance CNS infection and neuroinflammation, and are involved in the increased
blood–brain barrier (BBB) permeability, while is not clear if neopterin levels are associated with the
BBB permeability during HIV-1 infection [22]. However, the amount of neopterin levels is considered
a parameter to monitor the activation of immune system [26,27]. Other studies reported a correlation
between CSF neopterin levels and CSF neurofilament light protein (NFL)—a biomarker of neuronal
injury—in cART-treated HIV-1-positive patients [23]. Consequently, we chose to measure the neopterin
levels in CSF as a marker of the expression of brain immune activation, and our findings show a
significant decrease in CSF neopterin levels recorded in all HIV-1-positive patients after 6 months of
high concentration multistrain probiotic supplementation. From these data, we could speculate the
benefit of this high-concentration multistrain probiotic supplementation on the CNS inflammation
in treated HIV-1-positive patients and confirmed the role of neopterin as a biomarker of immune
activation in CSF. We also hypothesize that the neopterin level measured in the CSF is related to the
gut flora of the HIV-1-positive patients. In this regard, a fair number of studies have observed the
correlation between gut and brain [28,29]. Cryan et al. describes the gastrointestinal (GI) tract like
the scaffold that links the CNS and gut microbiota [28]. Several conditions, such as stress, depression
and HIV-1 infection, can modify the bidirectional communication between CNS and gut [30]. In this
regard, it is well known that dysbiosis occurs in the earliest phase of the HIV-1 infection, and it is able
to affect intestinal permeability [31–34] and mucosal immunity [35–37]. The mechanisms by which the
microbiota affects CNS function in HIV-1-positive subjects are various and still poorly understood.
They include inflammation and the alterations of immune activation that can directly affect the brain
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through the production of cytokines, microbial metabolites (e.g., short-chain fatty acids: n-butyrate,
acetate, and propionate) and through the alteration of tryptophan metabolism [29]. Tryptophan—an
essential amino acid introduced by diet—is absorbed in the gut, enters the circulation, and through
the BBB, arrives in the CNS [38,39]. A critical role in this context seems to be played by IDO; this
enzyme induced by many cytokines like IFN β and IFN γ, as well as by HIV-1—metabolizes a large
part of the tryptophan, generating kinurenine and some other metabolites. Quinlinic acid has been
associated with neuronal toxicity, lesions of the central nervous system, and neurocognitive disorders
in HIV-1-positive patients [2,10–13]. The dark side of IDO activity is a deregulation of the Th17/Treg
cells ratio, with a shift toward a tolerogenic immunity and a blunted T cell-mediated effector immunity,
contributing to the depletion of CD4+ T cells [6].
Our results show that probiotic supplementation of cART significantly reduces IDO mRNA
expression in the GALT. A positive correlation was also recorded between GALT-associated IDO
mRNA and CSF neopterin levels before probiotic supplementation. We speculate that IDO activity and
tryptophan metabolism are involved in the inflammation that occurs in the CNS, actively participating
in the onset of neurocognitive disorders observed during HIV-1 infection. Notably, a significant
reduction of both compounds after six months of probiotic administration has been recorded, which
can open the door to the management of neurological complications in people living with HIV-1
infection if confirmed by a larger study. Indeed, HIV-1 may penetrate inside the CNS alone and through
monocyte binding, cells which are able to cross the BBB [22]. The brain is an important reservoir of
HIV-1, but it remains unclear if the virus causes of persistent low-grade inflammation during cART, or
if the virus—after evolution and adaptation to the environment—drives an inflammatory response
in the brain [40,41]. The pivotal role of inducing a status of activation in the CNS is attributed to
monocyte-derived macrophages; monocytes entering the CNS differentiate into macrophages, and
during activation can produce several substances important in the pathogenesis of neurocognitive
disorders [42,43]. The opportunity to reduce the activation of the IDO pathway through this probiotic
product could break the vicious gut–brain circle and in this manner prevent the neurocognitive
impairment observed in HIV-1-positive patients.
Even though we found a correlation between IDO expression and neopterin levels prior to
supplementation with probiotics, after 6 months of probiotics supplementation, this correlation was
lost. We attributed this unexpected result to the lack of statistical power due to the small sample size
of patients analyzed.
This study was limited by the small sample size of patients analyzed, by the lack of evaluation
of IDO enzyme activity and tryptophan metabolites in the blood, and by a full assessment of liver
function. In fact, we evaluated only IDO mRNA expression in the GALT—which reflects the local rate
of activity of this key enzyme involved in tryptophan metabolism—but we were unable to assess the
“origin” of the high levels quinolinic acid at the enrollment. Furthermore, since tryptophan metabolism
has been indicated as the product of pathogenic gut bacteria [16], and since a decreased IDO1 activity
associated with a preservation of Th17 has recently been observed in chronic simian immunodeficiency
virus (SIV) infection after probiotic supplementation [44], it could be also important to look for changes
in the gut microbiome.
Finally, in consideration of the unregulated probiotic market and of the seriousness of the HIV
infection, it should be kept in mind that our results were obtained with a specific product and may not
apply to different probiotic products
4. Materials and Methods
4.1. Patients
Ten HIV-1-positive patients successfully treated with cART were recruited at the Division of
Infectious Diseases, Department of Public Health and Infectious Diseases, Hospital of “Sapienza”
University of Rome (Italy).
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The study was approved by the institutional review board (Department of Public Health and
Infectious Diseases, “Sapienza” University of Rome and the Ethics Committee of Umberto I General
Hospital, Rome, 2013). All study participants signed written informed consent. The inclusion
criteria used to enroll HIV-positive patients were the following: (i) individuals signed the informed
consent; (ii) women or men at least 18 years of age; (iii) in highly-active ART (HAART) with
HIV RNA <37 copies/mL and CD4 T cell counts >400 cells/mm3. Exclusion criteria were the
following: (i) patients with known allergy or intolerance to probiotics; (ii) diarrhea; (iii) history
of or current inflammatory diseases of the small intestine or drug addiction; (iv) use of antibiotics
or probiotics during the 3 weeks prior the enrollment; (v) pregnancy. All HIV-1-positive patients
received a high-concentration lyophilized multistrain probiotic powder supplement twice a day
for six months. The probiotic preparation daily dosage was 1.8 × 1012 live bacteria, according to
the previously reported studies [45,46]. The product containing the same strains present in the
preparation employed in our study (Lactobacillus plantarum DSM 24730, Streptococcus thermophilus
DSM 24731, Bifidobacterium breve DSM 24732, Lactobacillus paracasei DSM 24733, Lactobacillus delbrueckii
subsp. bulgaricus DSM 24734, Lactobacillus acidophilus DSM 24735, Bifidobacterium longum DSM 24736,
Bifidobacterium infantis DSM 24737) currently sold under the brand Vivomixx® in Continental Europe
and Visbiome® in USA and Canada.
4.2. Samples
Patients were sampled for peripheral blood and colonoscopy before and after probiotic
supplementation. Colonic washing was carried out by polyethylene glycol-electrolyte solution (PEG)
administration 24 h before the examination. The endoscopic procedure was performed with conscious
sedation (midazolam 5 mg/iv) using large cup forceps (Radial Jaw 4, Boston Scientific, Natick, MA,
USA). All HIV-1-positive patients underwent a total colonoscopy and retrograde ileoscopy for at least
10 cm of distal ileum with conventional or slim scope (model CF or PCF-160 AI, Olympus Medical
Europe GmbH, Hamburg, Germany). We obtained specimens (two biopsies from each site) from the
terminal ileum, cecum, ascending, transverse, and descending colon.
Lamina propria lymphocytes (LPLs) was stored as dried pellets for RNA extraction. Gut biopsies
from each intestine site were pooled and processed. Briefly, biopsies collected in RPMI 1640 were
washed twice with EDTA wash media, resuspended, and incubated for 1 h at room temperature in
EDTA solution 5 mM. Supernatant containing intraepithelial lymphocytes was removed, and biopsies
were digested by 1 h incubation at 37 ◦C with 1 mg/mL collagenase (Sigma-Aldrich, Milan, Italy) and
1.5 U DNAse I (Sigma-Aldrich), allowing the isolation of LPLs that were filtered through a 70 µm
cell strainer.
CSF was collected by lumbar puncture, centrifuged, and cell-free supernatant samples were stored
in aliquots at −80 ◦C.
4.3. ELISA Assay
CSF Neopterin levels of 10 HIV-1-positive patients were determined by a commercially available
solid phase enzyme-linked immunosorbent assay (ELISA) based on the basic principle of a competitive
ELISA (IBL International GmbH, Hamburg, Germany).
4.4. Real-Time PCR
Quantitative real-time PCR for IDO mRNA expression was carried out with the LightCycler 480
instrument (Roche, Basel, Switzerland). Briefly, total RNA was extracted from LPLs using the
RNeasy Plus Universal Tissue Mini Kit (Invitrogen, Carlsbad, CA, USA) and reverse transcribed
using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystem, Foster City, CA, USA),
according to the manufacturer’s protocol. Primers and probes for each gene were added to
the Probes Master Mix (Roche, Basel, Switzerland) at 500 and 250 nM, respectively, in a final
volume of 20 µL. The housekeeping gene β-glucuronidase was used as an internal control.
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Gene expression values were calculated by the comparative Ct method. The primers and
probe sequences used for IDO were the following (Forward 5′-GCATTTTTCAGTGTTCTT
CGCA-3′, Reverse 5′-CATACACCAGACCGTCTGATAGCT-3′, Probe5′-(6FAM) ATATTTGTCT
GGCTGGAAAGGCAACCCC (TAM)-3′) [47].
4.5. Statistical Analysis
Statistical analyses and graphic presentation were done on CSF and gut samples of
10 HIV-1-positive patients. In particular, neopterin determination and linear regression with
Spearman’s correlation coefficient were calculated using GraphPad Prism software, version 5.0
(GraphPad Software Inc., La Jolla, CA, USA), and data were compared by Wilcoxon test for paired
samples. IDO mRNA expression was analyzed using Primer-E software, version 6.0 (PRIMER-E Ltd.,
Lutton, UK), and data were compared using t-test. Differences were considered statistically significant
when p < 0.05.
5. Conclusions
In conclusion, the probiotic product employed in our study, when supplemented for 6 months
in HIV-1-positive patients, is associated with a significant reduction of the CSF neopterin and
GALT-associated IDO mRNA levels. Since the results for the use of adjunctive therapies to reduce the
levels of immune activation markers in CSF have been disappointing so far, our pilot study showing
the efficacy of this specific probiotic product should be followed by a larger confirmatory trial.
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